Harrow acquires global rights to TYVRAYA dry eye therapy
Harrow will acquire TYVRAYA nasal spray from Viatris for up to $100 million in cash and contingent milestones to expand its ophthalmic portfolio.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day